CD8A and cancer: Although cancer vaccines would ideally seek to elicit a cytotoxic T-cell response, measuring cancer-antigen-specific antibody release can act as a marker for effective immune response due to overlap with the underlying CD4+ repertoire needed for activating cytotoxic CD8+ T-cells (Fig. 5).